KPV (Lys-Pro-Val) – Comprehensive Research Overview (2026)
KPV (Lysine-Proline-Valine) is a naturally occurring C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of α-MSH without its melanotropic effects. KPV is primarily researched for its ability to reduce intestinal inflammation, modulate immune responses, and support wound healing. It is one of the most studied peptides for inflammatory bowel disease (IBD) models and is frequently combined with BPC-157 or TB-500 in regenerative protocols.
→ View KPV (for laboratory research use only)
Mechanism of Action
KPV exerts anti-inflammatory effects through multiple pathways:
- Binds to melanocortin receptors (MC1R, MC3R) on immune cells, reducing NF-κB activation and pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6).
- Directly enters cells and inhibits intracellular inflammatory signaling.
- Promotes intestinal epithelial barrier integrity and mucosal healing.
- Modulates macrophage and T-cell activity toward anti-inflammatory phenotypes.
Clinical Evidence and Research Findings
Extensive preclinical data in colitis, IBD, and wound healing models demonstrate significant anti-inflammatory and tissue-protective effects. KPV has shown efficacy in reducing colonic inflammation, improving barrier function, and accelerating wound closure. Human clinical data are limited, but its safety profile and mechanism make it a compelling candidate for IBD and inflammatory conditions research.
→ Interested in researching KPV? View Product Options
Benefits (Research & Clinical Observations)
- Potent anti-inflammatory effects in gut and systemic models
- Support for intestinal mucosal healing and barrier integrity
- Wound healing acceleration
- Immune modulation without immunosuppression
- Synergistic effects when combined with BPC-157 or TB-500
Typical Dosing Protocols (Off-Label / Compounded)
- Common protocols: 500 μg–2 mg per day (subcutaneous or oral)
- Oral use is being explored given its stability and gut-targeted effects
- Cycles: 4–12 weeks depending on indication
- Often combined with BPC-157 for enhanced GI and systemic repair
Safety Profile and Side Effects
KPV has shown a favorable safety profile in preclinical studies with no significant toxicity at effective doses.
Common side effects: Minimal reported; mild injection-site reactions possible.
Monitoring recommended: Standard inflammatory markers and GI function with prolonged use.
KPV vs BPC-157 vs α-MSH – Quick Comparison
| Aspect | KPV | BPC-157 | α-MSH |
|---|---|---|---|
| Primary Focus | Anti-inflammatory, gut healing | Tissue repair & cytoprotection | Melanotropic + anti-inflammatory |
| Melanotropic Effect | None | None | Yes (pigmentation) |
| Best For | IBD, gut inflammation | Tendons, gut, wounds | Broad anti-inflammatory |
| FDA Status | Not approved | Not approved | Not approved |
FAQ – Frequently Asked Questions
Is KPV FDA approved? No. It is available as a research chemical or through compounding pharmacies under physician supervision.
Can KPV be taken orally? Yes. Its small size and stability make oral administration viable, particularly for gut-targeted effects.
How does KPV compare to BPC-157 for gut health? KPV is more specifically anti-inflammatory via melanocortin pathways; BPC-157 has broader cytoprotective and vascular effects. They are often combined.
How long until results are seen? Anti-inflammatory effects in preclinical models appear within days to weeks.
Summary
KPV is a potent anti-inflammatory tripeptide derived from α-MSH with strong preclinical evidence for gut healing, immune modulation, and wound repair. Its favorable safety profile and oral bioavailability make it a versatile tool in regenerative and inflammatory disease research. As with all compounds in this library, KPV is not an approved drug and should only be considered under qualified medical supervision.
For Laboratory Research Use View KPV →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.